Home Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.11, p.785–792,2021

Journal info


 


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.2

 

Aims and Scope
Editorial Info
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.122, No.11, p.785–792,2021

Title: Therapeutic effect of mesenchymal stem cell therapy in the LVEF, LVEDV, and LVESV after myocardial infarction
Author: M. M. Rabiei, K. S. Khoramgah, I. A. Darazam, S. Vafaei-Nezhad, S. Dargahi, H. A. Abbaszadeh

Abstract: OBJECTIVES: The present study was aimed to investigate the therapeutic effect of mesenchymal Stem Cell Therapy in the left ventricular ejection fraction (LVEF), left ventricular enddiastolic volume (LVEDV), and  left ventricular endsystolic volume (LVESV) after myocardial infarction (MI).
BACKGROUND: Previous investigations propose that stem cell therapy may help treat myocardial infarction (MI). However, there are controversial data from different studies.
METHODS: We studied the relevant scientific literature available up to 2020. Comprehensive Meta-Analysis Software (CMAS) Version 2.0 were used for statistical analyses. Fixed or random-effect model was used to identify the weighted mean difference (WMD) with 95% confidence intervals (CI). The statistically significant level used for interpreting publication bias was less than 0.05.
RESULTS: We identified 30 studies that met the inclusion criteria. In the overall pooled estimate, cell therapy had an effect on the LVEF change from baseline to follow-up (WMD: 2.98 mL, 95% CI: 1.66 to 4.29). The pooled WMD was found to be –4.16 (95% CI: –7.91 to –0.40) and –5.62 (95% CI: –9.20 to –2.00), for LVEDV, and LVESV, respectively. Thus, reduction in LVEDV and LVESV were significant in the treatment group participants.
CONCLUSIONS: The present systematic review indicated that cell therapy in patients, who have MI could be effective and applicable clinically (Tab. 3, Fig. 7, Ref. 48). Text in PDF www.elis.sk

Keywords: myocardial infarction, stem cell, systematic review, randomized clinical trials
Published online: 21-Oct-2021
Year: 2021, Volume: 122, Issue: 11 Page From: 785, Page To: 792
doi:10.4149/BLL_2021_125


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.